Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Double-blind Placebo Clear all
Completed Phase 1 Interventional Results available

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

NCT04478708
View directory record Official record
Conditions
Obesity
Interventions
maridebart cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Anaheim, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Placebo, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

NCT02382016
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Macitentan, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn

NCT01037452
View directory record Official record
Conditions
Heartburn
Interventions
Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
2,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 27, 2026, 5:30 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Dex as Analgesic Adjuvant in OSA Patients

NCT03613558
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

NCT07143448
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
HS235, Placebo
Biological · Other
Lead sponsor
35Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449878
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 27, 2026, 5:30 AM EDT
Not listed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

NCT04780685
View directory record Official record
Conditions
Covid19
Interventions
hMSC
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fullerton, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

NCT00426985
View directory record Official record
Conditions
Tendonitis, Bursitis
Interventions
Ketoprofen Topical Patch 20%, Placebo
Drug · Other
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

NCT05353985
View directory record Official record
Conditions
Celiac Disease
Interventions
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

NCT03400943
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
52
States / cities
Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional

The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes

NCT00982293
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resonator device, Resonator device - sham
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

NCT02163993
View directory record Official record
Conditions
Migraine Headache
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Encino, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting Phase 4 Interventional

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

NCT02630121
View directory record Official record
Conditions
Sleep Apnea, Chronic Nasal Congestion
Interventions
Oxymetazoline Hydrochloride, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

NCT01396421
View directory record Official record
Conditions
Acute Schizophrenia
Interventions
OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional

Treatment of Bacterial Vaginosis With Oral Tinidazole

NCT00229216
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Tinidazole
Drug
Lead sponsor
Mission Pharmacal
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

NCT00104416
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic
Interventions
lamotrigine (LAMICTAL) extended-release, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
64
States / cities
Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

NCT00446433
View directory record Official record
Conditions
Crohn's Disease
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
12 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Tucson, Arizona • Anaheim, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 27, 2026, 5:30 AM EDT